Chapter 36: Drug Development

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today we are plunging headfirst into one of the most intellectually thrilling and honestly challenging areas of science.

The intersection of pure biochemistry and practical life -saving medicine.

It really is.

We're talking about the rigorous, often brutal process of drug development.

Right.

It's where all this beautiful theoretical chemistry meets the, well, the messy reality of human physiology.

It is messy.

And when you boil down a molecule's entire journey from discovery to a pharmacy shelf, you realize the stakes are just incredibly high.

I mean, a successful drug can't just be effective.

It has to be almost flawless just to survive inside the human body, let alone cure a disease.

That's exactly.

So our mission today is pretty straightforward.

We're giving you the shortcut.

We're going to walk through this comprehensive chapter summary, hitting the critical molecular, physiological, and clinical hurdles involved in turning one promising chemical compound into a medicine you can actually use.

And we have to start with the targets themselves.

We aren't, you know, aiming vaguely at a disease.

We are aiming at specific, highly evolved proteins.

Okay.

What are the main classes of targets?

Based on pretty much all the drugs currently in use,

the vast majority modulate one of three main classes of their molecules.

And those are?

First up, you have enzymes.

These are often inhibited to just stop an undesirable reaction.

Think of blocking a key step and making cholesterol or halting the replication engine of a virus.

Okay.

That makes sense.

What's the second class?

Receptors.

These are huge families, like the G protein coupled receptors that span the cell membrane or the nuclear receptors inside the cell.

And by modulating those, we can control cell signaling.

Exactly.

You can send, block, or even misdirect signals that regulate almost everything a cell does.

And the third group?

Transporters.

These are basically the gatekeepers that manage what goes in and out of our cells.

So that would include things like ion channels.

Yep.

Salute carriers, which shuttle things like

and the absolutely critical ion channels, which govern the excitability of our neurons and muscle cells.

These three protein types are really central to modern medicine.

So let's say we find a specific enzyme that's hyperactive in a cancer cell.

We design a molecule to block it.

That sounds like a pure biochemistry problem.

It does, doesn't it?

But this is the central challenge, the thing that tanks, what, 99 % of all promising candidates.

The molecule has to be so much more than just a potent blocker in a test tube.

That is the ultimate bottleneck.

The compound has to satisfy two wildly different sets of criteria.

The first is that molecular challenge.

It must be a potent modulator of its target.

And the second?

The second is the physiological challenge.

And it's often the harder one.

It has to navigate the body safely and efficiently.

Which means it has to be easy to take, right?

Ideally, yes.

We always prefer oral administration, you know, a small tablet.

It has to survive the stomach, avoid being instantly destroyed by the liver.

And this is critical reach its target in a high enough concentration.

While avoiding everything else.

While avoiding every other biomolecule it might bump into.

That last point, selectivity, is really the line between a medicine and a poison.

Absolutely.

Lack of selectivity is where all the dangerous side effects come from.

It's the primary driver, yes.

So let's start with that molecular side of things.

How do biochemists even measure if a drug candidate is successfully binding to its target?

We begin with pure affinity.

Any drug candidate that binds to a target protein is called a ligand.

And the strength of that interaction is quantified by something called the dissociation constant, TDD -DALR.

Okay, TDD -DALRs.

What does that number actually tell us?

You can think of it as a measure of how easily the drug and target complex falls apart.

So a low DDD means it's a very strong tight interaction.

High affinity.

We're usually looking for a DALR in an anomalous range or even lower.

But a strong bond isn't the whole story, is it?

I mean, a ligand could bind like superglue, but if it doesn't actually do anything useful in the cell, it's worthless.

That's the next step.

We have to measure the biological effect.

That's when we move to functional assays where we use terms like EC50 or IC50.

EC50, that's the effect of concentration.

Exactly.

It's the concentration you need to get 50 % of the maximum biological response.

So if you're testing an antibiotic, the EC50DALR is the concentration needed to kill half of the bacteria.

And sometimes 50 % isn't enough.

Sometimes you need more certainty.

So we might look for the ECDALR, which guarantees a 90 % effect.

And for inhibitors, which are often what we're looking for with cancer or chronic diseases.

Then we use IC50DALR and IC50DALRs, the inhibitory concentration.

So the IC50 is the concentration of your inhibitor that you need to reduce a response, say the activity of an enzyme by 50%.

Okay.

So those values tell us about potency in a real system, like a cell culture.

Yes.

In a functional system, not just a test tube with two purified molecules.

Now for the selectivity hurdle, this sounds incredibly difficult.

If our target is a human protein, it probably has dozens of evolutionary cousins in our body that look almost identical.

It can feel nearly impossible.

Evolution is messy and related proteins, especially within big signaling families, often share these highly conserved binding domains.

So if your drug accidentally binds to one of those off -target proteins, even if that binding is 10 times weaker, that can translate into a really nasty side effect, especially if that secondary protein governs a totally different crucial system.

So how do you quantify that?

How do you know you're selective enough?

You look at the ratio of the ticoble values.

You compare the ticoDALRs for the off -target binding versus the ticoDALR for your intended target.

You want that ratio to be massive.

That example.

If the nothing but tDALRs for your target is, say, one nanomolar and the tbDALR for a related off -target is one micromolar, that's a thousand -fold difference.

That usually gives you excellent selectivity.

But then there's the added complication that the drug is competing in vivo with the body's own chemistry,

with the natural ligands that are supposed to be there.

Precisely.

This makes the drug's effective

IC50DALR a moving target.

How so?

Well, if your drug is a competitive inhibitor, meaning it binds to the exact same site as the natural substrate, its effectiveness depends directly on how much of that substrate is floating around.

So if a patient has naturally high levels of the substrate, the drug has to work much harder.

Much harder.

It has to fight to get onto that binding site and maintain its 50 % inhibition.

And this is where the pure math of the Chang -Prusoff equation becomes so important conceptually.

It is.

The relationship is IC50DALR equals quantity one plus the substrate concentration over DALRs.

So what does that actually tell a doctor or a pharmacist?

It's the mathematical proof that a drug's effective dose is always changing, depending on the patient's internal state.

The ticDALRs is the drug's intrinsic power, that's fixed.

But the IC50 you actually need is directly proportional to how much natural substrate a ticDALR is present.

So if a patient is, say, stressed or inflamed, and their body floods the system with that natural substrate.

That goes way up.

Then the drug we thought had a great IC50 suddenly becomes way less effective.

Exactly.

The ratio of ICDALR over DALR increases, and that drives the required IC50 for the drug higher and higher.

It's a critical realization.

A fixed number from a lab test doesn't reflect the dynamic reality of the human body.

Wow.

Okay, so that sets the stage for the molecular requirements.

Now, the molecule has to survive its journey.

This brings us to the pharmacokinetic gauntlet, ADME properties.

Right.

ADME.

Absorption, distribution, metabolism, and excretion.

If a compound fails any one of these four, it does not matter how potent it is, it will never be a useful drug.

Because it just can't maintain an effective concentration over time.

Correct.

Let's start with absorption A, an oral bioavailability.

We want to take a pill, but swallowing a pill seems to activate every defense mechanism the body has.

It really does.

An oral drug has to survive the incredibly harsh acidic gut.

Then, to even get into the bloodstream, it has to pass through the intestinal cell membranes.

That physical passage is a huge hurdle.

Which is why big molecules like proteins or antibodies have to be injected.

Almost universally, yes.

They just can't make that crossing.

So how do we measure the success rate of absorption?

We use a metric called oral bioavailability.

It's a ratio.

You compare how much drug gets into the bloodstream after you swallow it versus how much gets in from a direct injection.

So if you inject 100 milligrams, you get 100 milligrams in the blood.

Right.

100 % bioavailability.

But if you swallow that same 100 milligrams and only 30 milligrams makes it into circulation, your bioavailability is 30%.

And low bioavailability means you need huge doses, which is expensive and can cause side effects in the gut.

Exactly.

This challenge led to the creation of Lipinski's rules, which are famous rules of thumb for predicting poor absorption.

Okay, what are the four main red flags that suggest a molecule is going to fail this test?

So these are generalizations, but they're very useful.

Poor absorption is likely if, one, the molecular weight is over 500.

Okay.

Too big.

Two, the number of hydrogen bond donors is greater than five.

Three, the number of hydrogen bond acceptors is greater than 10.

And four, the partition coefficient is greater than five.

I want to dig into the biochemistry of those.

Yeah.

Why do too many hydrogen bond donors or acceptors make a molecule hard to absorb?

Think about what it has to do.

A molecule with lots of those groups is highly polar.

It forms really stable, tight interactions with the water molecules all around it.

It loves being in water.

It loves being in water.

And across the fatty cell membrane, all of those hydrogen bonds have to be broken first.

That requires a lot of energy.

So a drug that's locked into the water phase has low membrane permeability.

And that brings us to the partition coefficient.

This sounds like the molecule has to have a split personality.

It's the ultimate Goldilocks problem for a drug.

Log measures how much the compound prefers to be in an organic fatty phase versus the watery aqueous phase.

So you need a high poetie to be lipid soluble enough to sneak across the membrane.

You do.

But Lipinski's rule warns against a log greater than five.

It can be too fat soluble.

How is that a problem?

Well, if the log's too high, the drug acts like a motor oil.

It crosses the membrane easily, but then it can't dissolve in the watery environment of the blood and the cytoplasm.

It just gets stuck in fatty tissue.

So it needs a delicate balance.

Yeah.

Soluble enough in fat to cross, but soluble enough in water to travel.

That's the tightrope it has to walk.

And these are just guidelines.

The book mentions morphine satisfies all of Lipinski's rules, but its bioavailability is only around 33%.

Right.

Biology is always more complicated.

There are other factors like active transport systems or metabolism happening right in the gut wall that can override these simple

Okay.

So once it's absorbed, the drug has to navigate the body.

Distribution.

D.

How do these small, often hydrophobic compounds even travel in the blood?

They don't travel alone.

They bind extensively to circulating carrier proteins, mainly L -Gumin, which basically acts as a fairy service.

And then the drug distributes into different compartments.

Yes.

The blood, the fluid between cells, the brain, different tissues, and only the drug that reaches the correct target

counts.

Distribution elsewhere just lowers the effective dose.

And for any drug targeting the brain, there's the ultimate barrier,

the blood brain barrier, the BBB.

It's essentially the body's ultimate bouncer.

The cells lining the capillaries in the brain have extremely tight junctions between them.

It's a hyper selective filter designed to keep almost all foreign compounds out.

A massive challenge for neuroscience.

One of the single greatest challenges.

Yes.

Next up, metabolism.

M.

This is the body's defense system against foreign or xenobiotic compounds.

This is the liver trying to destroy the molecule we worked so hard to make.

And it is brutally efficient at it.

Drug metabolism rapidly decreases the concentration of the compound.

The general goal is to make a hydrophobic drug more water soluble so it can be excreted.

This usually happens in two phases.

Phase I transformations.

This is where the famous cytochrome P450 enzymes come in.

Right.

Phase I is usually an oxidation reaction and it's driven by over 50 different types of cytochrome P450 enzymes or P450s mostly in the liver.

They add an oxygen atom usually creating a hydroxyl group.

Which does two things right.

Increases water solubility and creates a handle for the next step.

Precisely.

A simple example is the hydroxylation of ibuprofen.

That new hydroxyl group is the handle for phase two transformations, the conjugation step.

So it's conjugation.

This is basically the chemical labeling phase.

The body attaches large highly water soluble groups to the molecule.

Things like glutathione, glucuronic acid or sulfate.

And these giant tags make the molecule super water soluble and easy to excrete.

Yes and they act as labels that the liver and kidney can recognize for efficient removal.

Now there's a fascinating exception you mentioned earlier.

Monoxidil.

Metabolism actually makes it more active.

It's a great example.

Monoxidil is used for hair growth but it's actually the metabolic product monoxidil sulfate that's the more active compound.

The body's own sulfation enzymes inadvertently activate the drug.

For oral drugs the liver gets a huge head start on this destruction through something called first pass metabolism.

This is a major major problem for oral bioavailability.

All the blood leaving your intestine flows through the portal vein directly to the liver.

So the drug gets hit with the full metabolic force of the liver before it even reaches the rest of the body.

Exactly.

The liver can destroy a huge fraction of the dose on this first pass dramatically limiting how much of the drug is actually available.

Finally excretion.

E.

The body has to get rid of the drug and its metabolites.

What are the main routes?

The primary route is through the kidneys.

Blood is filtered and water soluble compounds that aren't reabsorbed get excreted in the urine.

The second major pathway is through the bile.

The liver actively transports compounds into the bile which then gets excreted in the stool.

And sometimes the body even recycles the drug.

Yes.

Entero hepatic cycling.

Some compounds that get excreted into the intestine via the bile actually get reabsorbed back into the blood.

This recycling loop can really prolong the drug's All of these processes, ADME, determine the drug's half -life.

Right.

The half -life is the time it takes for the body to eliminate 50 % of the drug.

It's a critical value.

A drug with a long half -life might be a convenient once -a -day pill.

A short half -life means you're taking it three or four times a day which is much harder for patients to stick with.

Okay, now let's talk about the sharp edges of this process.

Toxicity and the therapeutic index.

A drug has to help, not harm.

Where does toxicity come from biochemically?

It usually falls into three categories.

First, over -modulation of the intended target.

You're just hitting the right target too hard.

Think of an anticoagulant like Coumadin.

A good dose prevents clots.

Too high a dose causes life -threatening bleeding.

Makes sense.

What are the other two?

Second, modulating related proteins.

The grug hits those evolutionary cousins we talked about, causing off -target effects.

And third, modulating entirely unrelated proteins.

This is where you get really unexpected problems, like compounds that block the HERG potassium channel, which can cause fatal cardiac arrhythmias.

And toxicity can actually be generated by the body's own defense system during metabolism.

The example of acetaminophen overdose is terrifying.

Can you walk us through that?

It's a crucial lesson.

At normal doses, acetaminophen is safe.

But in high doses, a specific P450 enzyme in the liver oxidizes it, creating a highly reactive, very damaging intermediate called N -acetylpipenzocanone iminine.

That does not sound like a friendly molecule.

It is not.

Normally, the liver is prepared.

It has a big supply of glutathione, or GSH.

You can think of glutathione as the liver's dedicated chemical fire extinguisher.

GSH rapidly attaches to that toxic metabolite, neutralizing it, and the harmless product is then excreted.

So what happens in an overdose?

The patient overwhelms the system.

The production of the toxic metabolite outpaces the liver's ability to make more glutathione.

The fire extinguisher runs out.

And then?

With no defense left, that reactive molecule is free to attack and irreversibly damage essential liver proteins, leading to acute liver failure.

It's why acetaminophen poisoning is so dangerous and can require an emergency transplant.

Wow.

And this whole balancing act of risk is summarized by the therapeutic index.

Right.

The therapeutic index is our final measure of safety.

It's the ratio of the LD50, the dose that's lethal to 50 % of test animals, to the EC50, the effective dose.

And you want a massive gap between those two numbers.

A huge gap.

A ratio of a thousand is considered very safe.

A ratio of five or ten means the difference between a therapeutic effect and a catastrophic one is razor thin.

Now that we understand these almost impossible requirements, the next big question is,

where do we even find these miracle molecules?

We'll start with discovery by serendipity, or chance observation.

Serendipity is when you accidentally observe a desirable physiological effect, often long before you have any idea what the molecular target is.

The greatest example, the one that launched the age of antibiotics, is penicillin.

Alexander Fleming, 1928.

The moldy petri dish.

That's the one.

He noticed that his staphylococcus bacteria colonies were dying wherever they got close to a contaminating mold, penicillium notatum.

He realized the mold was producing some kind of antibacterial substance.

And the biochemistry, which came much, much later.

Penicillin has this unique strain four -membered ring called a beta -lactam ring.

This structure is a chemical weapon.

It allows penicillin to bind to and permanently block a critical transpeptidase enzyme that bacteria use to build their cell walls.

So without that wall, the bacteria just fall apart.

They're susceptible to osmotic lysis, yes.

Another amazing example is chlorpromazine, or thorazine.

Right.

That was discovered while researchers were actually looking for better antihistamines to treat surgical shock.

But they noticed that patients given the compound became remarkably calm and detached.

Which led to its revolutionary use in treating psychosis.

Exactly.

We now know it works by blocking dopamine D2 receptors in the brain.

A total accident.

And maybe the most famous serendipitous discovery of the 20th century, sildenafil or Viagra.

Right.

Sildenafil was developed to inhibit an enzyme called phosphodiesterase 5, or PDE5.

The hope was that it might help with cardiovascular issues.

But during early clinical trials, the male subjects reported a very specific and unexpected side effect.

Increased penile erections, yes.

Biochemically, it makes perfect sense.

PDE5 breaks down a signaling molecule called CGMP.

By inhibiting the enzyme, sildenafil keeps CGMP levels high, which promotes smooth muscle relaxation and vasodilation in blood vessels.

That observation created a multi -billion dollar market.

So from pure luck, we move to a more systematic approach.

Discovery by screening natural products.

This feels ancient, but it's still so productive.

The classic example here is aspirin.

Its origins go all the way back to Hippocrates using willow bark for pain relief.

The active ingredient salicylic acid was eventually isolated, but it was really harsh on the stomach.

And then Felix Hoffman at Bayer made a slight chemical modification.

He developed the less irritating derivative acetyl salicylic acid aspirin.

And the mechanism is just beautiful biochemistry.

What does that little acetyl group do?

It's stunningly specific.

That acetyl group is transferred to a single serine residue right near the active site of the enzyme cyclooxygenase.

This covalent modification physically blocks the active site, shutting down the production of pain and inflammation signals.

It's far more effective than the original molecule.

The other huge success from natural products are the statins, which completely changed how we treat high cholesterol.

The key here was identifying the right target, HMG -CoA reductase.

It's an early, rate -limiting step in the cholesterol synthesis pathway.

And choosing an early step was important, wasn't it?

Crucial.

Earlier attempts to block later steps in the pathway led to the toxic buildup of insoluble intermediates.

HMG -CoA reductase was a safer target because its substrate is water -soluble, so inhibiting it doesn't cause a toxic traffic jam.

And these compounds, the first statins, came from fungi.

Yes.

Researchers screened fermentation broths and found compactin from penicillium, and then lovastatin from aspergillus.

And statins have this brilliant dual action.

They lower cholesterol synthesis, but they do something else, too.

They also cause cells to increase the expression of the LDL receptor on their surface.

So not only are you making less cholesterol, your body gets better at actively pulling the harmful LDL cholesterol out of your bloodstream.

The success of screening nature led logically to the next step.

Discovery by screening synthetic libraries and combinatorial chemistry.

If nature is good, maybe we can be better.

That's the rationale behind high -throughput screening, or HTS.

You use automated robotic systems to test hundreds of thousands or even millions of compounds against a target.

And to make those huge libraries efficiently, we use combinatorial chemistry.

How does that work?

It's about exponential efficiency.

Imagine a molecule with two spots you can customize.

If you have 20 different chemical building blocks for site 1 and 4e for site 2, you only run 60 reactions.

But you end up with a library of $20 x 40 equals $800 unique compounds.

The split pool synthesis method is the clever trick for actually doing this, right?

Using those little beads.

It's a brilliant method.

You use these small resin beads.

You start with a big pool of them, split them into, say, 10 containers and do a different reaction in each.

Then, and this is the key, you pull them all back together and mix them thoroughly.

Then you split that mixed pool again into another 10 containers and do a second set of reactions.

Because of that mixing step, each individual bead ends up with only one unique final compound on its surface, but the entire pool contains, in this case, 100 different compounds.

It's an incredibly efficient way to manage it.

But even with millions of compounds, we have to acknowledge the sheer size of what's possible.

Oh, absolutely.

The estimated number of possible drug -like small molecules is something like 10 to the 60th power.

It's a number so vast it's hard to comprehend.

Screening millions of compounds is an engineering triumph, but it's still just a tiny drop in an infinite ocean.

And that limitation pushes us toward the most intellectually demanding method,

structure -based drug design,

the ideal lock -and -key scenario.

The goal here is to design the perfect key for the lock.

You use techniques like x -ray crystallography to get an atomic -level picture of your target protein's binding site, and then you try to design a molecule that fits it perfectly.

A huge success story here was the development of HIV protease inhibitors.

It was a perfect target.

The protease is essential for the virus to mature.

Initial designs yielded inhibitors that were potent but had terrible bioavailability.

They just didn't work in people.

So how did they break through?

They used the x -ray structures to design a hybrid compound, indintover, that combined the best features of two of the weaker inhibitors into one new molecule.

And that led to this intensive optimization process, studying the structure -activity relationship, or SAR.

And the data from that process showed this really counterintuitive trade -off.

This is one of my favorite stories in drug development.

The researchers were measuring both inhibitory power, the IC50 dollar, and physiological performance in animals,

the maximum concentration in the blood, or CMAC.

What did they find?

The compound they ultimately selected for development, the one that became a blockbuster drug, actually had the weakest inhibitory power, the highest IC50 dollars of all the final candidates.

Wait, they chose the weakest one?

Why on earth would they do that?

Because it had, by far, the best bioavailability.

It reached the highest concentration in the blood.

The realization was profound.

A B -grade inhibitor that actually gets to its target is infinitely better than an A -plus inhibitor that gets destroyed by the liver or can't be absorbed.

Bioavailability trumps pure potency.

At the end of the day, yes.

You have to solve the physiology problem.

Another powerful example of this structure -based approach is the COX2 -specific inhibitors.

This is about achieving selectivity.

Right.

We have two very similar cyclooxygenase enzymes, COX1, which is always on, and COX2, which is induced by inflammation.

They're over 60 % identical, making them very hard to target separately.

So how did X -ray crystallography reveal the secret?

The crystal structures showed one single key difference.

The COX2 enzyme has an extended binding pocket that is completely absent in COX1, just a little extra space.

Because of a single amino acid difference.

A bulky isoleucine in COX1 is a smaller valine in COX2.

That's it.

So the design strategy was obvious.

Build a molecule with a bulky part.

Exactly.

They synthesized compounds with a protuberance, a chemical group that would fit snugly into that unique COX2 pocket, but would physically clash with the wall of the smaller COX1 active site.

And that gave us drugs like Celebrex.

It yielded highly selective drugs like Celecoxib and Rofocoxib, a stunning demonstration of molecular engineering.

This also brings us back to that cautionary tale with Vioxx.

It does.

While Vioxx was perfectly selective for its target, it was later withdrawn from the market because of adverse cardiac effects that were detected years later.

It's a reminder that even when you hit your target perfectly,

inhibiting that target can still have complex, unexpected consequences for the whole system.

Let's shift now to the modern era, where genomics is providing the map to new medicines.

We're talking about identifying novel targets in the human proteome.

Right.

With the human genome sequenced, we have the full catalog.

This has drastically accelerated target identification.

We know there are roughly 21 ,000 proteins.

And we can focus on large target -rich families.

Yes, families that are particularly prone to modulation by small molecules.

Two stand out.

First, the protein kinases.

There are over 500 of them, and they are often the drivers of diseases like cancer.

Think of the BCR -able kinase targeted by Gleevec.

And the second family.

The 7TM receptors are G protein -coupled receptors.

There are about 450 of these, not counting the ones for smell.

They regulate almost every aspect of physiology and are the targets for huge drug classes like beta blockers.

And how do we find completely novel targets outside these known families?

We look for differences.

We compare diseased cells to healthy cells.

We look for proteins that are over - or under -produced, or located in the wrong part of the cell, or have unusual chemical modifications.

So you have a potential target.

You still have to prove that hitting it will actually help a patient.

That brings us to validating targets using animal models.

The mouse is our primary workhorse here.

The mouse and human genomes are about 85 % identical.

The key technique is creating gene knockout mice, where you genetically disrupt a specific gene.

And then you see what happens.

You see what happens.

If knocking out the gene cures the disease model or produces the predicted effect, you've just validated your target.

Is there a good example of this kind of retrospective validation?

A great one is the protein responsible for secreting acid into the stomach, the TxHR +, TxK +, ATPase.

When scientists created knockout mice that lacked this protein, their stomach pH rose dramatically from a very acidic 3 .2 to a much more neutral 6 .9.

That's a massive change.

It is.

And it retrospectively proved that this single protein was the correct target for anti -acid drugs like Prilosec.

The animal model confirmed the biochemical logic with sound.

And genomics is just as powerful for fighting pathogens, right?

Finding targets in pathogen genomes.

Nika gives us a huge advantage.

By sequencing pathogen genomes, we can search for proteins that are essential for the pathogen's survival, but are completely different from any human proteins.

Which maximizes selectivity and minimizes side effects.

Exactly.

This is urgent for finding new broad -spectrum antibiotics.

We look for highly conserved essential proteins across many bacteria, like peptide deformeles, which is involved in protein synthesis.

We saw this strategy play out in real time during the SARS outbreak.

We did.

The SARS coronavirus genome was sequenced with incredible speed.

And that sequence immediately revealed a gene for a viral protist that's essential for the virus to replicate.

Knowing that structure instantly opened the door for designing targeted antiviral drugs.

This whole discussion about genetics leads us to the crucial topic of pharmacogenetics.

Why do different people respond so differently to the same drug?

It's all about genetic variation.

Some people have slight differences in the structure of the drug's target, which affects binding.

Or, more commonly, they have variations in the ADME proteins that process the drug.

Pharmacogenetics is all about tailoring drug choice and dose to an individual's genotype.

Let's start with a target variation example.

The blood pressure drug metoprolol.

Right.

Metoprolol is a beta blocker.

Studies found its effectiveness depends entirely on which version, or allele, of the beta -1 adrenergic receptor a patient has.

People with two copies of the most common allele get a great response.

But people with a different variant?

Those with two copies of a specific variant allele show essentially no therapeutic response at all.

Knowing the patient's genotype beforehand tells the doctor if the drug is even worth trying.

And what about genetic variation in the ADME process, in metabolism?

This is where things can get dangerous.

Take the thiopurine drugs used in leukemia treatment.

Toxicity is often caused by variations in a metabolizing enzyme called TPMT.

Some patients have variants that produce an unstable or inactive enzyme.

Which means they can't break the drug down properly.

Exactly.

The drug builds up to toxic levels.

It's now standard practice for physicians to patients' TPMT genotype before prescribing these drugs so they can adjust the dose, which has dramatically improved safety.

So we've found our candidate,

optimized it, and validated the target.

Now comes the most expensive and time -consuming stage.

Clinical trials.

Yes.

The FDA mandates ironclad proof of effectiveness and safety.

And the cost has soared to well over $800 million per drug.

It starts with Phase I.

Phase I is a small group, 10 to 100 people, usually healthy volunteers.

The only goal here is initial safety.

You're just looking at how the drug is tolerated and metabolized in humans.

Efficacy is not evaluated at all.

Then Phase II, which shifts the focus to whether the drug actually works.

Phase II uses a small group of the actual target patients.

The focus is now on efficacy and finding the right dose while still collecting safety data.

And crucially, these trials are often controlled and double -blinded.

Why is that double -blinded, controlled structure so critical?

To rule out bias,

specifically the incredible power of the placebo effect.

A controlled study randomly assigns people to get either the real drug or a placebo.

Double -blinding means neither the patient nor the doctor knows who is getting what.

And the placebo effect, where you feel better just because you believe you're getting treatment, is shockingly powerful.

It's astonishing.

There was a famous study on arthroscopic knee surgery where the placebo group who received a sham surgery reported the exact same level of improvement as the group that got the real procedure.

Wow.

It shows you have to use this rigorous design, or you might approve a drug that works purely on the power of belief, not on its biochemistry.

After Phase II confirms efficacy, Phase III goes big.

Phase III involves a massive diverse population, thousands of patients.

The goal is to firmly establish efficacy across a wide demographic, and really importantly, to detect low -frequency side effects that you'd never see in a small study.

And even after approval, the journey isn't over.

There's Phase IV.

Phase IV is post -approval surveillance.

It's monitoring the drug after it's on the market, used by millions of people to catch any long -term or very rare side effects.

The Vioxx withdrawal was a result of Phase III monitoring.

Finally, we have to talk about the biggest, most dynamic challenge in medicine.

Drug resistance.

This is where evolution fights back.

It's purely an evolutionary problem.

Infectious diseases and cancer are characterized by huge populations that mutate and reproduce incredibly fast.

The drug acts as a powerful selective pressure.

So any random mutation that helps the bug or the cell survive the drug?

Gains a massive fitness advantage and quickly takes over the whole population.

The resistance to HIV protease inhibitors is a prime example of how fast this can happen.

HIV's reverse transcriptase enzyme makes a lot of mistakes.

It has no proofreading.

The mutation rate is astronomical.

It's estimated that every possible single -point mutation happens over a thousand times a day in just one infected person.

So a mutation that makes the protease resistant to a drug is guaranteed to pop up quickly?

Very quickly.

And those resistant viruses then dominate, which is why combination therapy is essential.

Antibiotic resistance is also spreading, often because the resistance mechanism is portable.

Right.

Bacteria can acquire enzymes that destroy the drug.

For example, beta -lactamase enzymes that chew up penicillin.

The genes for these enzymes are often carried on plasmids, small circles of DNA that can be transferred between bacteria, even across species.

Like trading resistance tools?

Exactly.

And cancer cells do the same thing?

Yes.

With their inherent genetic instability, tumors recur after treatment with targeted drugs like Gleevec because the cancer cells accumulate mutations in the drug's target, the BCR -ABL kinase, so the drug can no longer bind.

And then there's the final challenge of multiple drug resistance.

This is a nightmare scenario.

Cancer cells can become resistant to many different drugs at once by over -expressing ABC transporter proteins.

These are basically molecular pumps.

Pumps.

Yes.

Highly efficient energy -dependent pumps that sit in the cell membrane and actively push the drug molecules right back out of the cell, keeping the intracellular concentration too low to be effective.

What a journey.

We've gone from single molecule binding constants all the way to global evolutionary arms races.

To quickly recap the essentials, drugs target enzymes, receptors, and transporters.

They have to overcome the brutal gauntlet of ADME, where things like Lipinski's rules help predict success.

And we find them through luck, massive screening, or elegant design.

And the future is all about genomics validating targets, finding pathogen -specific vulnerabilities, and through pharmacogenomics, finally tailoring treatments to an individual's unique genetic makeup.

So here's a final thought for you to take away.

This whole discussion about resistance, it shows that biochemistry is never static.

We are locked in this constant evolutionary arms race with pathogens and cancer.

So if every successful drug just creates a selective pressure for resistance to evolve.

Right.

How does that change the fundamental goals of drug discovery?

Should we be focusing less on finding the single perfect inhibitor and more on developing therapies that prevent the evolution of resistance in the first place, maybe by hitting multiple targets at once?

A fascinating question.

Thank you for joining us for this deep dive.

We hope this has given you the conceptual tools to really understand the incredible complexity of modern medicine.

Thanks for tuning in.

We'll see you next time.